Type 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening
Accordingly, screening for T1D-associated autoantibodies in individuals with a personal or family history of AIDs, and vice versa, should be implemented in clinical practice.
Authors
- M. Schott (ORCID: https://orcid.org/0000-0002-3034-9305)
- René D. Rötzer (ORCID: https://orcid.org/0009-0001-6667-5188)
- Monika Kellerer (ORCID: https://orcid.org/0000-0002-9834-5976)
- Thomas Först (ORCID: https://orcid.org/0000-0003-2132-5691)
- Stefanie Lanzinger (ORCID: https://orcid.org/0000-0002-3789-6459)
- George J. Kahaly (ORCID: https://orcid.org/0000-0003-0441-430X)
- Petra‐Maria Schumm‐Draeger
Institutions
- Technische Hochschule Mannheim (DE)
- Zimmer Biomet (Netherlands) (NL)
- University of Mannheim (DE)
- Universität Ulm (DE)
- Johannes Gutenberg University Mainz (DE)
- Düsseldorf University Hospital (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Marienhospital Stuttgart (DE)
- Zimmer Biomet (Germany) (DE)
- Clinical Research Services (DE)
- Research Center for Energy Economics (DE)
- WEK Tierarzt (DE)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Endocrinology Diabetes & Metabolism
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1002/edm2.70119
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Amarin Corporation
- Daiichi-Sankyo
- Eisai
- Novo Nordisk
- Ipsen
- Sanofi-Aventis Deutschland
- Cilag